Rolf stahel biography of barack

Mutations in the epidermal growth factor receptor (EGFR) have served as the basis for using targeted therapies with tyrosine kinase inhibitors (TKIs) in patients with advanced non—small cell lung cancer (NSCLC); however, it is now known that the response duration to EGFR TKIs is short-lived for patients who harbor the exon 20 T790M mutation, and T790M has been recognized as the most common mechanism of TKI drug resistance.

 Recent research has been aimed at expanding treatment options for patients with T790M NSCLC, who are typically treated with cytotoxic chemotherapies. 

EGFRT790M: Some Recent Findings

• Recent, back-to-back publications in theNew England Journal of Medicinehave demonstrated the clinical activity of two next-generation TKIs, AZD9291 and rociletinib, in patients with T790M mutation and disease progression while on first- or second-generation EGFR TKIs.